The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of azacitidine (5-AZA) with or without birinapant in subjects with higher risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML).
 
William Bruce Donnellan
No Relationships to Disclose
 
Maria Diez-Campelo
Honoraria - Celgene; Novartis
Consulting or Advisory Role - Boehringer Ingelheim
Speakers' Bureau - Celgene; Novartis
Research Funding - Celgene (Inst); Janssen-Cilag (Inst); Novartis (Inst)
 
Michael Heuser
Honoraria - Celgene
Consulting or Advisory Role - Novartis; Sunesis Pharmaceuticals
Research Funding - Bayer Schering Pharma (Inst); BerGenBio (Inst); Daiichi Sankyo (Inst); Illumina (Inst); Karyopharm Therapeutics (Inst); Pfizer (Inst); Sunesis Pharmaceuticals (Inst); TetraLogic Pharmaceuticals (Inst)
 
Ellen K. Ritchie
Consulting or Advisory Role - Incyte
Speakers' Bureau - Celgene; Incyte
Travel, Accommodations, Expenses - Celgene
 
Jeffrey Skolnik
Employment - GlaxoSmithKline; TetraLogic Pharmaceuticals
Stock and Other Ownership Interests - GlaxoSmithKline; TetraLogic Pharmaceuticals
 
Patricia Font
No Relationships to Disclose
 
Rami S. Komrokji
Stock and Other Ownership Interests - Abbvie
Consulting or Advisory Role - Celgene; Incyte; Novartis
Speakers' Bureau - Incyte; Janssen Scientific Affairs; Novartis
Research Funding - Celgene (Inst); Eleos (Inst); GlaxoSmithKline (Inst); Incyte (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; Celgene; Incyte; Novartis